GL1X · GenesisL1 explorer

MolNFT v1 · #38471 · protein

Crystal structure of the E9 DNase domain with a mutant immunity protein IM9 (Y55A)

2GZE · Colicin-E9 immunity protein: “Crystal structure of the E9 DNase domain with a mutant immunity protein IM9 (Y55A)”. X-ray diffraction, 2 ligands (ZN, PO4), 2 pockets (best druggability 0.39). MolNFT v1 #38471 on GenesisL1: 3D…

PDB
2GZE
Type
protein
Length
214 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Colicin-E9 immunity protein; Colicin-E9
EC
3.1.21.1
UniProt
P13479, P09883
Ligands
ZN, PO4
Pockets
2 · best druggability 0.39

Structure

x-ray diffraction · 2 distinct chains · 49% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AColicin-E9 immunity proteinprotein8259% helix, 2% strandP13479
BColicin-E9 (EC 3.1.21.1)protein13243% helix, 17% strandP09883

Ligands and binding sites

  • ZN · Zinc ion · metal · chains B
  • PO4 · Phosphate ion · ion · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1720.390.7920empty
21290.370.7322PO4

Interfaces

1 interface between chains.

  • A–B · 786 Ų buried · 17 hydrogen bonds · protein-protein

Compared structures

  • 2GZE · Crystal structure of the E9 DNase domain with a mutant immunity protein IM9 (Y55A) · the same entry in another collection · chain A against A, TM-score 1.00
  • P13479 · AlphaFold monomer V2.0 prediction for colicin-E9 immunity protein (P13479) · a predicted model of the same protein · chain A against A, TM-score 0.98
  • P09883 · AlphaFold monomer V2.0 prediction for colicin-E9 (P09883) · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.